D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave Quantum Inc. (NYSE: QBTS) ("D-Wave"), a leader in quantum computing systems, software and services, will release its financial results for the third quarter of fiscal year 2025 ended September 30, 2025 on Thursday, November 6 before market open. The press release will be available on the D-Wave Investor Relations website: https://ir.dwavesys.com/. In conjunction with this announcement, D-Wave will host a conference call on Thursday, November 6, 2025, at 8:00 a.m. (Eastern Time), to discuss the Company's financial results and business outlook. The live dial-in number is 1-844-826-3035 (domestic) or 1-412-317-5195 (international). Participants can use those dial-in numbers or can click this link for instant telephone access to the event.

Participating in the call will be Chief Executive Officer Dr. Alan Baratz and Chief Financial Officer John Markovich.

To view the full press release, visit https://ibn.fm/XiwV7

A new artificial intelligence feature designed to help shoppers identify online scams has drawn praise from the UK's minister for fraud. The tool, called Scam Intelligence, allows customers of Starling Bank to upload listings and images from online marketplaces such as eBay, Facebook Marketplace, Etsy, and Vinted. It then analyzes the content for potential red flags and offers tailored guidance on whether a deal might be fraudulent. Fraud minister Lord Hanson described the innovation as a powerful example of how technology can help protect consumers. Starling developed the system using Google's Gemini AI in partnership with Google Cloud, and it was officially presented at a fintech conference in Las Vegas earlier this week. Most users during testing employed Scam Intelligence for smaller purchases such as trainers and event tickets. The bank said it is the first UK financial institution to integrate an AI-driven scam detection service directly into its mobile app. Starling noted that participation is voluntary; customers can choose to enable Scam Intelligence within the bank's app. As more advanced technologies are commercialized by entities like D-Wave Quantum Inc. (NYSE: QBTS), more sophisticated anti-scam tools are likely to become available to banks and other client-facing institutions. 

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Thursday's trading session at $36.11, up 5.3999%, on 44,418,015 volume. The average volume for the last 3 months is 67,427,280 and the stock's 52-week low/high is $0.975/$46.75.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - New AI Anti-Scam Tool Gets Praise from Key UK Minister
• BillionDollarBreaks - D-Wave Quantum to Report Third Quarter Fiscal Year 2025 Financial Results on November 6, 2025
• AMD Shares Jump as IBM Says its Existing Chips Can Correct Quantum Computing Errors

Beeline Holdings Inc. (NASDAQ: BLNE)

The QualityStocks Daily Newsletter would like to spotlight Beeline Holdings Inc. (NASDAQ: BLNE).

Beeline Holdings (NASDAQ: BLNE) , the digital mortgage lender built for next-generation homeowners, locked 21 loans totaling nearly $8 million on Oct. 29, the same day the Federal Reserve announced its second consecutive rate cut, marking record highs for the company's key performance indicators. The Rhode Island-based lender, which declared itself debt-free in September and expects to be cash-flow positive by Q1 2026, credits its AI-driven proprietary platform for its ability to rapidly scale as market conditions improve.

To view the full press release, visit https://ibn.fm/qI1aG

Beeline Holdings Inc. (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive user experiences to simplify home financing. Through wholly owned subsidiary Beeline Loans Inc., the company delivers fast and flexible loan solutions for both primary homebuyers and real estate investors. Beeline has built an end-to-end digital lending ecosystem designed to eliminate friction, reduce costs, and dramatically shorten closing timelines.

Since completing its October 2024 merger with Eastside Distilling, Beeline has solidified its position as a next generation fintech mortgage originator. Its core vision centers on digitizing the mortgage journey with tools like AI chatbot Bob, proprietary production engine Hive, and an expanding SaaS product suite. These innovations enable Beeline to close loans in just 14–21 days—less than half the industry average—while achieving a Net Promoter Score above 80, more than four times higher than the sector benchmark.

Beeline’s mission is to make home loans effortless by giving users instant access to rate quotes, approvals, and document uploads—all online, 24/7. Having surpassed $1 billion in cumulative loan originations and achieved 38% year-over-year growth, Beeline is scaling its platform across the U.S. mortgage and real estate investing landscape.

The company is headquartered in Providence, Rhode Island.

Products

Beeline operates a fully digital, AI-enabled loan origination and title ecosystem. Key features include:

• Bob 2.0 – The industry’s first AI mortgage agent, available 24/7/365 to quote rates and pre-approve borrowers; Bob has delivered 6x lead conversion and 8x full application volume compared to traditional loan officers.
• Hive – A task-based processing engine that replaces manual workflows with scalable automation, cutting loan closing times to as little as 14 days.
• BlinkQC – Beeline’s proprietary AI quality control platform that replaces costly third-party reviews.
• Beeline Title – A fully diversified title services unit supporting digital collateral transfer, remote closings, and investor-focused solutions.
• MagicBlocks – A customizable AI sales agent platform developed by Beeline and spun out into its own entity; Beeline retains equity and licensing rights, positioning it to benefit from future growth and deployment of the technology.

The company also provides Debt Service Coverage Ratio (DSCR), bank statement, and conventional mortgage products tailored to investors, including short-term rental operators. Strategic partnerships with Rabbu and Red Awning streamline property analysis, financing, and management within a single ecosystem.

Market Opportunity

The U.S. mortgage market is poised for growth in 2025, with total mortgage origination volume expected to increase by 28% to $2.3 trillion, up from $1.79 trillion in 2024. This projection includes a 13% rise in purchase originations to $1.46 trillion.

Within this expanding market, investor lending, particularly through DSCR loans, represents a rapidly growing segment. DSCR loans, which are underwritten based on the income generated by the property rather than the borrower’s personal income, are ideal for real estate investors, particularly those purchasing long-term or short-term rental properties. Beeline has strategically positioned itself in this niche, with over one-third of its volume derived from DSCR products. Through its affiliate referral network and integrations with platforms like Rabbu, the company is actively expanding its market reach in this high-margin category.

Non-agency mortgage issuance, which includes DSCR loans, is projected to reach $160 billion in 2025, a 16% increase from 2024.

Leadership Team

Nick Liuzza, Chief Executive Officer, co-founded Beeline Mortgage LLC in 2019 after selling Linear Title & Closing and Linear Settlement Services to Real Matters. He also previously built New Age Nurses into a national staffing firm. He currently serves as EVP of Real Matters (TSX: REAL).

Jess Kennedy, Chief Operating Officer, is a co-founder of Beeline with 15 years of legal and real estate experience. She previously served as General Counsel and Chief Compliance Officer at Beeline and held roles at Solidifi, LeClairRyan, and Edwards Wildman Palmer LLP, handling complex real estate finance and title transactions.

Chris Moe, Chief Financial Officer, joined Beeline in 2023 with over 40 years of finance and investment banking experience. He has held senior roles at Red Cat Holdings (NASDAQ: RCAT), IRIS Therapeutic Devices, and Yates Electrospace Corporation, bringing deep public company and defense sector expertise.

Beeline Holdings Inc. (NASDAQ: BLNE), closed Thursday's trading session at $2.97, up 1.7123%, on 335,481 volume. The average volume for the last 3 months is 914,343 and the stock's 52-week low/high is $0.6202/$10.5.

Recent News

• Beeline Holdings Inc. (NASDAQ: BLNE) - InvestorNewsBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Sets Record Loan Volume Following Fed Rate Cut Announcement
• CryptoNewsBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) CEO Highlights Blockchain Home-Equity Platform Launch in Exclusive Benzinga Interview
• CryptoNewsBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Achieves Industry First with Blockchain-Recorded Home Equity Transactions

Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG)

The QualityStocks Daily Newsletter would like to spotlight Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG).

The price of gold dropped below $4,000 an ounce as easing trade tensions between China and the United States triggered a selloff. Spot gold slipped by over 3% to reach $3,980 per ounce, with diplomats from both countries preparing a series of achievements for Chinese leader Xi Jinping and President Donald Trump to announce at their upcoming summit this week. The trade deal between the world's two largest economies could help reduce certain economic uncertainties and geopolitical strains that have supported demand for the precious metal. The surge that pushed gold to an all-time high of just over $4,380 an ounce last week has since reversed amid indications that the metal had entered overbought territory. Recent gains were fueled by expectations of the Federal Reserve reducing interest rates, which attracted retail investors, helping drive prices higher. Speaking at the event, John Reade of the World Gold Council explained that while central bank demand had eased, many dealers would welcome a deeper market correction. He added that discussions at the conference pointed to around $3,500 per ounce as a healthy level for the precious metal's market given that it was still a remarkable high price. Gold may gain support this week as major central banks meet, with expectations that the Federal Reserve will reduce rates slightly, while the Bank of Japan and the European Central Bank could retain existing rates, potentially boosting demand for the non-interest-bearing metal. Companies like Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) that are involved in gold production will be watching keenly as the major central banks make their interest rate decisions that could affect the gold market. 

Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) is the operator of the Waterberg Project, a bulk underground platinum group metals (PGM) deposit discovered by Platinum Group in 2011 and located on the Northern Limb of the Bushveld Complex in South Africa. The Waterberg Project is planned as a fully mechanised platinum, palladium, rhodium and gold mine, including by-product copper and nickel production, and is projected to be one of the largest and lowest cost PGM mines globally.

The project is a joint venture between Platinum Group; integrated PGM producer Impala Platinum Holdings Ltd. (OTCQX: IMPUY); Japanese consortium HJ Platinum, which includes trading house Hanwa Co. and the government-backed Japan Organization for Metals and Energy Security (JOGMEC); and local empowerment partner Mnombo Wethu Consultants (Pty) Ltd. Platinum Group has an effective 50.22% interest in the Waterberg Project.

The company’s primary business objective is to advance the Waterberg Project to a development and construction decision. An update to the 2019 Definite Feasibility Study is expected in 2024.

PGMs are essential and precious metals that include platinum, palladium, rhodium, iridium, osmium and ruthenium. These metals are known for their purity, high melting points and unique catalytic properties. They are utilized in a number of industrial processes, technologies and commercial applications and play a critical role in autocatalysis and pollution control in the automotive sector. The bulk of global PGMs are mined in Southern Africa and Russia.

The unique properties of PGMs are being applied to various technologies as possible solutions for more efficient energy generation and storage, which may create new demand for PGMs. The company’s battery technology initiative through Lion Battery Technologies Inc., using platinum and palladium in lithium battery technologies, represents one such new opportunity in the high-profile lithium battery research and innovation field.

Platinum Group Metals Ltd. founded Lion Battery Technologies Inc. in partnership with Anglo American Platinum Ltd. (AMS: JNB) to support the use of palladium and platinum in lithium battery applications. Lion Battery has entered into an agreement with Florida International University to further advance a research program that uses platinum and palladium to unlock the potential of Lithium Sulfur (Li-S) battery chemistries.

Platinum Group is headquartered in Vancouver, B.C., and Johannesburg, South Africa.

Waterberg Project

Platinum Group’s sole material mineral property, the Waterberg Project, is presently in process with pre-construction permitting; engineering work, including road upgrade and traffic studies; finalization of power and water infrastructure design; and construction camp design.

The company’s principal product from the Waterberg Project is planned to be a PGM-bearing concentrate. The concentrate will contain economic amounts of six elements comprising platinum, palladium, rhodium, gold, copper and nickel. The company’s partner in the Waterberg Project, Impala Platinum Holdings, has acquired a right of first refusal to enter into an offtake agreement, on commercial arm’s-length terms, for the smelting and refining of mineral products from the Waterberg Project.

The Waterberg project has proven and estimated reserves of 19.5 million ounces of PGMs and gold. When fully operational, the mine is projected to produce more than 400,000 ounces of PGMs annually during the peak period of steady state production. The life of the mine is projected at 45 years.

South Africa’s PGM mining sector remains closely tied to economic developments in the global automotive industry, which in 2022 accounted for approximately 43% of the total global demand for platinum and 82% of the total global demand for palladium.

Market Opportunity

According to a report from Straits Research, a global market and business research firm, the worldwide platinum market had an estimated value of $7.72 billion in 2022 and is projected to reach $11.95 billion by 2031. That represents a CAGR of 5.13% over the forecast period.

Platinum, one of the rarest of precious metals, is about 30 times scarcer than gold. It is crucial to the automotive and electronics industries and is also used to make jewelry. Stricter emissions regulations around the world have led to an increased demand for platinum to be used in catalytic converters to reduce automotive emission, the report states.

A report from Allied Market Research estimated the global palladium market at $16.3 billion in 2021 and projects the market will reach $28.6 billion by 2031, growing at a CAGR of 5.8% over the period.

Palladium is also used in automotive catalytic converters for reducing emissions and in jewelry, dentistry, watchmaking, blood sugar test strips, aircraft spark plugs, surgical instruments, electrical contacts and musical instruments.

An increase in demand for consumer electronics has driven demand for palladium-based multilayer ceramic capacitors (MLCC) used to store energy in electronic devices such as broadcasting equipment, mobile telephones, computers, electronic lighting and high voltage circuits, according to the report.

Management Team

Frank R. Hallam is Co-Founder, Director, President and CEO of Platinum Group. He has over 30 years of experience in the mining, minerals and petroleum industry as an operator, principal and founder. He was a co-founder and former CFO of MAG Silver Corp. He was also co-founder and director of West Timmins Mining Inc. and a director of Lake Shore Gold Corp. In addition, he was CFO and director with gold exploration company Tan Range Exploration Corp. He is a Chartered Professional Accountant and was formerly an auditor in the public mining practice of PwC. He holds a Bachelor of Business Administration from Simon Fraser University.

Greg Blair is CFO of Platinum Group. He has been with Platinum Group since 2010 in various roles, most recently as Interim CFO. Prior to joining Platinum Group, he was at a public accounting firm working on public company (mainly mining) audits. He is a Chartered Professional Accountant and holds a degree in Economics from Simon Fraser University and has completed the Canadian Securities Course.

Kris Begic is VP Corporate Development of Platinum Group. He has over 25 years of experience in the mining industry and capital markets and has been involved with the raising of over $500 million for various exploration and development projects globally. His efforts are focused on project generation, mergers and acquisitions, capital markets, investor relations and marketing.

Platinum Group Metals Ltd. (NYSE American: PLG), closed Thursday's trading session at $2.3, up 1.3216%, on 1,231,875 volume. The average volume for the last 3 months is 4,273,036 and the stock's 52-week low/high is $0.99/$3.36.

Recent News

• Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG) - Trade War Truce Between China, the US Triggers Gold Selloff
• Investor Interest Piqued as the Price of Platinum Surges
• Should You Acquire Gold Before the Upcoming Federal Reserve Meeting?

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

HeartBeam (NASDAQ: BEAT) , a medical technology company transforming cardiac care through personalized insights, will hold a conference call on Thursday, Nov. 13, 2025, at 4:30 p.m. ET to discuss its third quarter results for the period ended Sept. 30, 2025. The Company will also provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones. A detailed press release will be issued prior to the call.

To view the full press release, visit https://ibn.fm/5mXsb

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company pioneering a new approach to cardiac care by delivering hospital-grade electrocardiogram (ECG) insights outside traditional clinical settings. Its proprietary platform supports a scalable app-based solution for real-time heart monitoring.

The company’s mission is to empower both patients and physicians with actionable cardiac data wherever symptoms begin, addressing a critical gap in the first hours of cardiac events. Through its connected cardiac care ecosystem, HeartBeam is establishing a new model for remote monitoring that deepens patient engagement and delivers more actionable insights for physicians. This approach is designed to obtain early diagnosis which could reduce time to treatment, improve outcomes, and lower costs across the healthcare continuum.

HeartBeam’s system aims to bring clinical-grade cardiac assessment into the home. HeartBeam is preparing for commercial launch as its 12-lead ECG synthesis software undergoes regulatory review, building on prior clearance of its 3D ECG system for arrhythmia assessment. The company plans to leverage its unique longitudinal ECG dataset and deep learning algorithms to advance predictive capabilities in the future.

HeartBeam is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship innovation is its credit card-sized, cable-free ECG device that collects heart signals in three non-coplanar dimensions and synthesizes a 12-lead ECG. Cleared by the FDA in December 2024 for arrhythmia assessment, the HeartBeam System enables patients to capture high-fidelity heart data during symptomatic episodes, even outside a clinical environment.

The company’s pending 12-lead ECG synthesis software, developed from the same 3D signal acquisition, successfully met clinical endpoints in the VALID-ECG study and is currently under FDA review for arrhythmia assessment. This software combined with an on-demand cardiologist reader service is expected to form the backbone of HeartBeam’s commercial launch strategy, providing patients with access to a synthesized 12-lead ECG outside of the traditional hospital setting and enabling physician interpretation of patient ECGs from anywhere.

From the core, the team is building an ecosystem that includes integration with wearables, automated arrhythmia assessments, AI-driven wellness features, community features and trending insights. The ecosystem is intended to drive adoption and increase the overall value of the HeartBeam System.

Artificial Intelligence and Predictive Analytics

To enhance its diagnostic capabilities, HeartBeam is developing AI-powered arrhythmia detection algorithms to be validated in collaboration with Mount Sinai Heart. In early testing, these deep learning algorithms achieved diagnostic accuracy comparable to standard 12-lead ECGs when classifying atrial fibrillation, atrial flutter, and sinus rhythm.

Additionally, HeartBeam’s AI engine has the potential to transform routine monitoring into predictive power in the future. The company’s platform enables frequent readings, building a unique longitudinal ECG dataset unique that no one else offers. By leveraging deep learning on the repeated measurements, there is an opportunity to develop predictive capabilities, such as screening for hidden cardiac conditions and forecasting risk of future events. The unique longitudinal dataset will create a defensible data moat as the company continues to advance its AI program.

Market Opportunity

HeartBeam is targeting a large unmet need in cardiac care by delivering hospital-grade ECG diagnostics to patients outside of traditional healthcare settings. Cardiovascular disease is the leading cause of death worldwide, yet most cardiac events occur at home, where standard 12-lead ECGs are not available, leading to costly delays in diagnosis and treatment. HeartBeam’s FDA-cleared 3D ECG technology is designed to close this critical gap with on-demand, remote diagnostic capabilities.

The company’s initial commercialization strategy focuses on two distinct U.S. entry markets. The first includes approximately 500,000 elevated-risk patients in concierge care settings, representing a $250 million to $500 million annual revenue opportunity. The second addresses a larger direct-pay segment of 2.6 million elevated-risk individuals, with potential revenues of $1.3 billion to $2.6 billion annually. Future expansion may include reimbursement-driven pathways through Medicare Advantage, providers, and payer partnerships.

HeartBeam anticipates annual subscription pricing between $500 and $1,000 per patient, with roughly 50% gross margins on device costs and 70%+ on recurring revenue. Based on a model using five U.S. regions, each with an estimated 75,000 eligible patients, HeartBeam projects that just 10% adoption would generate approximately $20 million in gross profit—enough to reach cash flow break-even under current pricing and margin assumptions. Over time, the company’s longitudinal ECG dataset and predictive AI capabilities are expected to deliver additional value to healthcare systems, research institutions, and life science partners.

Leadership Team

Robert Eno, Chief Executive Officer and Director, brings over 30 years of experience in the medical technology industry, including leadership roles at HeartFlow, OptiMedica, and NeoGuide Systems. He joined HeartBeam as President in January 2023 and was appointed CEO in October 2024, later joining the board in May 2025 to support commercial growth.

Branislav Vajdic, Ph.D., Founder and Chief Technology Officer, is a semiconductor and medtech innovator who previously led product design teams at Intel and founded NewCardio. He holds over 20 patents and is the original architect of HeartBeam’s core technology.

Tim Cruickshank, Chief Financial Officer, oversees financial strategy and capital allocation. He works closely with the leadership team to support commercialization while maintaining financial discipline aligned with key regulatory milestones.

Peter Fitzgerald, M.D., Ph.D., Chief Medical Advisor, is Director of the Center for Cardiovascular Technology at Stanford and a seasoned clinical trialist with over 175 studies and 650 publications. He has founded over 20 medtech companies and advises the FDA on digital health analytics.

Ken Persen, Chief Technology Officer, has more than 28 years of experience in cardiac rhythm management and digital health. He previously served as CTO and CEO at LIVMOR and held engineering roles at Cameron Health and Guidant.

HeartBeam Inc. (NASDAQ: BEAT), closed Thursday's trading session at $1.61, up 0.625%, on 33,063 volume. The average volume for the last 3 months is 76,994 and the stock's 52-week low/high is $0.9101/$3.48.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Schedules Third Quarter 2025 Conference Call for Nov. 13
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Partners with HeartNexus to Deliver 24/7 Remote Cardiology Services and Real-Time ECG Interpretation
• InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Combining Portability and Precision to Redefine Future of Cardiac Care

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF)

The QualityStocks Daily Newsletter would like to spotlight MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF).

MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) today announced its inclusion in a NetworkNewsWire ("NNW") editorial titled "The Clean-Energy Revolution That Could Power the AI Era." The feature highlights how surging global energy demand from artificial intelligence (AI) and data centers is driving the search for scalable clean-energy solutions, with natural hydrogen emerging as a leading contender. Positioned as the first publicly traded company in North America focused on commercial natural hydrogen, MAX Power is at the forefront of efforts to meet the growing electricity needs of the expanding digital economy.

To view the full press release, visit https://nnw.fm/NM1Eu

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) is a Canadian mineral exploration company pioneering the development of natural hydrogen as a potential new primary energy source. As a first mover in this emerging sector, the company has assembled North America’s largest permitted land package targeting naturally occurring, emissions-free hydrogen accumulations in the earth’s subsurface.

MAX Power plans to commence Canada’s first dedicated deep drilling program for natural hydrogen in November 2025, starting on the 200-km-long Genesis Trend in southern Saskatchewan, with the goal of converting a discovery into the world’s first commercial natural hydrogen venture in 2026.

Backed by institutional partnerships and a highly experienced technical team, MAX Power continues to build a globally recognized brand in the natural hydrogen sector. Its massive land package in Saskatchewan currently comprises 1.3 million permitted acres with another 5.7 million acres under application.

Saskatchewan, a jurisdiction recognized for its supportive regulatory environment and clean energy innovation, features North America’s most advanced policy framework for the exploration and development of natural hydrogen. The province is also known for its spectacular resource endowment as the world’s leading potash provider, the top high-grade uranium producer in the world, and Canada’s second-largest oil producer. Saskatchewan is also Canada’s leader in helium production, geothermal energy and carbon capture.

The company’s head offices are in Saskatchewan’s two largest cities, Saskatoon and Regina.

Projects

Natural Hydrogen (Saskatchewan)

MAX Power holds multiple large land packages across Saskatchewan prospective for deposits of natural hydrogen, highlighted by the 200-km-long Genesis Trend and the 75-km-wide Grasslands Project.

Genesis features easy road, rail and power access and a proposed hydrogen hub on its eastern side where there is an abundance of potential end-users for natural hydrogen. Drilling is set to begin in early November 2025 at the Lawson target situated in the heart of Genesis. Canada’s first deep well for natural hydrogen is specifically designed to test a complete five-element hydrogen system interpreted to exist at Lawson: source rocks, migration pathways, reservoirs, seals, and traps. Data from vintage and proprietary 2D seismic, gravity and magnetic surveys, and subsurface mapping, among other geological and geophysical information, support the prospectivity of Lawson which lies adjacent to an extensive regional “Salt Barrier” offering excellent seal and trap conditions.

The Genesis Trend’s scalability is further demonstrated by the recent identification of the Lucky Lake target, approximately 50 km northwest of Lawson and one of at least 20 Lawson “look-a-likes” that is being investigated along the trend. Early interpretation suggests serpentinized rocks and structural features favorable for hydrogen generation exist at Lucky Lake.

At Grasslands, geologists are excited about a broad area in the vicinity of a well (“Climax”) near the U.S. border that was drilled a few years ago and inadvertently resulted in Canada’s first known deep subsurface occurrence of natural hydrogen, associated with a rare rock assemblage geologists refer to as “exotic terrane”. Permits covering an area stretching 75 km east-west and up to 10 km north-south were acquired by MAX Power next to this discovery, amplifying the company’s first-mover advantage. Adjacent to three sides of Grasslands are producing helium wells owned by privately-held North American Helium, demonstrating that this under-explored area of the province is highly prospective for clean gas. Drilling of a target at Grasslands is expected during Q1 2026.

Other MAX Power land packages are Rider 1, 2 and 3 in the southeast part of the province, and Choiceland in the north-central part of the province.

To enhance scientific rigor and accelerate development, MAX Power has established a multi-year strategic collaboration with the Petroleum Technology Research Centre (PTRC), a globally recognized leader in subsurface energy research based in Regina, Saskatchewan. This partnership complements the company’s relocation to Innovation Saskatchewan’s R+T Parks in Saskatoon and Regina, placing its technical and executive teams at the heart of the province’s academic, regulatory, and infrastructure ecosystem.

Critical Minerals

MAX Power’s other key asset is its Wilcox Lithium Project in mining-friendly Cochise County in southeast Arizona where first-ever diamond drilling in late 2023/early 2024 confirmed the discovery of near-surface lithium-rich clays over a broad area of the Willcox Playa. MAX Power’s property occurs within a nearly 4,000-acre corridor adjacent to U.S. Department of Defense land, and benefits from direct access through roads, rail and power infrastructure. The discovery was made just as lithium entered its final price downturn and is now being intensely revisited by the company in light of the turnaround in lithium and an emphasis on critical mineral resource development in the United States under the Trump administration.

Market Opportunity

According to company materials, the global hydrogen market is valued at approximately $250 billion and is expected to surpass $400 billion by 2030. Supporting this outlook, a study published in Science Advances (Dec. 2024) estimates that in-place natural hydrogen resources could meet global net-zero carbon goals for roughly 200 years. Closer to home, a feasibility study by the Transition Accelerator (April 2024) projects that the Regina-Moose Jaw Industrial Corridor (RMJIC) in Saskatchewan could support a C$708 million annual hydrogen market, with province-wide demand reaching as high as C$2.7 billion per year.

These projections underscore a compelling opportunity to establish a new energy economy centered around natural hydrogen—a low-cost, low-emission, and potentially naturally replenishing resource. MAX Power is well-positioned to lead this effort with proximity to infrastructure, favorable geology, and increasing institutional support.

Leadership Team

Mansoor Jan, CEO, brings more than two decades of international experience across mining operations, capital markets, and business development. He has held senior positions at BHP Australia, BHP Chile, and Rio Tinto, where he was responsible for advancing cross-border projects, driving mine optimization, and leading technology delivery across major jurisdictions. Mr. Jan holds a BA and MSc in Economics and a Master of Commerce from the University of New South Wales in Australia.

Neil McMillan, Director and Chair of the Audit Committee, is the former Chairman of the Board of Cameco, the world’s largest publicly traded uranium company. Mr. McMillan served on Cameco’s board for 16 years and is highly regarded within and outside the province for his decades of success there. He previously led Claude Resources as President and CEO, paving the way for its development into Saskatchewan’s only profitable gold miner which was bought out for more than $300 million by Silver Standard Resources in 2014.

Steve Halabura, Chief Geoscientist, has decades of successful experience in the province’s resource sector including a deep understanding of the geological controls on the accumulation of hydrogen, helium, and other industrial gases. He was also instrumental in the early formative stages of the only two Saskatchewan greenfield potash mines to come into existence in the 21st century, these being BHP’s Jansen Project and K+S’s Bethune mine. Jansen is the largest private investment ($14 billion) in Saskatchewan history and is located northeast of MAX Power’s Genesis Trend.

Tom Kishchuk, MAX Power’s Senior Strategic Advisor for Natural Hydrogen Development, is CEO for the Saskatchewan-based Global Institute for Energy, Mines and Society (GIEMS). He has over three decades of technical and business leadership in national and global organizations focused on the energy sector.

MAX Power Mining Corp. (OTC: MAXXF), closed Thursday's trading session at $0.4445, up 1.0227%, on 1,887,366 volume. The average volume for the last 3 months is 869,070 and the stock's 52-week low/high is $0.105/$0.532.

Recent News

• MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) - NetworkNewsBreaks - MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) Featured in NetworkNewsWire Editorial on Natural Hydrogen's Role in Powering the AI Era
• AINewsBreaks - MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) Unveils AI-Assisted Large Earth Model Integration for Natural Hydrogen Exploration
• InvestorNewsBreaks - MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Featured in NetworkNewsWire Editorial on Natural Hydrogen as Solution to AI Energy Demand

Bollinger Innovations, Inc. (NASDAQ: BINI)

The QualityStocks Daily Newsletter would like to spotlight Bollinger Innovations, Inc. (NASDAQ: BINI).

France has begun testing a motorway system capable of recharging electric vehicles as they travel on the A10 route nearly 25 miles southwest of Paris. Engineers embedded induction coils beneath 0.9 miles of asphalt on the A10 motorway and connected them to electrical power supplies controlled through software and sensor systems. Dubbed ‘Charge as You Drive', it is a collaboration between Electreon, VINCI Autoroutes, Hutchinson, Gustave Eiffel University, and VINCI Construction to test the feasibility of dynamic wireless charging technology under real traffic conditions. However, the EV industry will have to address various challenges before the technology can be deployed at scale. This includes installation costs, standardization across manufacturers, and receiver compatibility. If the French trial and future tests are successful, they could speed up EV adoption by making charging a seamless experience that doesn't require planned stops at charging stations. In the meantime, motorists will have to depend on the capacity of the rechargeable in-built batteries in electric vehicles made by enterprises like Bollinger Innovations, Inc. (NASDAQ: BINI) that require a stopover at a charging facility once the battery gets depleted. 

Bollinger Innovations, Inc. (NASDAQ: BINI) is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with United States-based manufacturing located in Tunica, Mississippi.

In August 2023, Mullen began commercial vehicle production in Tunica. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The Company’s commercial dealer network consists of Papé Kenworth, Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key West Coast, Midwest, Pacific Northwest, New England, and Mid-Atlantic markets.

In September 2022, Bollinger Motors, of Oak Park, Michigan, became a majority-owned EV truck company of Mullen Automotive. Bollinger Motors has passed numerous milestones including its B4, Class 4 electric truck production launch on Sept. 16, 2024, and the development of a world-class dealer network with over 50 locations across the United States for sales and service support.

Mullen Commercial

Mullen is defining a new era in commercial vehicles with its connected and customized solutions aimed at making businesses more efficient and profitable.

Mullen ONE Class 1 EV Cargo Van

The Mullen ONE class 1 commercial electric vehicle is the first of its kind in the U.S. market. This van was designed to navigate within narrow urban streets and residential roads, all while maximizing payload and cargo space. The Mullen ONE’s height is less than 6.5 feet, meaning your driver can park the vehicle in a residential garage.

Mullen THREE Class 3 Electric Truck

The efficient urban utility low cab forward features a tight turning diameter of 38 feet and excellent visibility for superior maneuverability on narrow city streets. Even in reverse, maneuverability is a breeze with our standard backup camera and 7-inch display screen. This versatile chassis provides a clean top-of-rail for easy upfitting with bodies up to 14 feet long and over 5,300 lbs of payload. In addition, the design of the LCF chassis allows more cargo length within a given overall length.

Mullen Commercial EVs are eligible for several federal and state level EV incentives, which can be combined for maximized savings.

Mullen ONE:

• $7,500 Federal Tax Credit
• $3,500 MOR-EV Incentive (Massachusetts only)
• $7,500 ComEd Business & Public Sector EV Rebate Program (Illinois only)

Mullen THREE:

• $7,500 Federal Tax Credit
• $45,000 California’s Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) (California only)
• $15,000 MOR-EV Incentive (Massachusetts only)
• $30,000 ComEd Business & Public Sector EV Rebate Program (Illinois only)

In the last two years, Mullen has conducted over 100 vehicle demos or pilots across various industries in the U.S. resulting in significant progress, including new sales opportunities and vehicle orders received and or completed:

• Universities: Princeton University, University of Virginia (UVA), University of California, Los Angeles (UCLA)
• Local city governments: Cities of Dublin, Ohio, Raleigh, North Carolina, Los Angeles, California, Seattle, Washington and Orange County, North Carolina
• Small businesses: From local florist shops to health care providers delivering supplies

Mullen has an extensive dealer network in the U.S. with renowned dealers nationwide including:

• Papé Group (California, Oregon, Washington)
• National Auto Fleet Group (California)
• Pritchard EV (Iowa)
• Eco Auto (Massachusetts)
• Ziegler Truck Group (Minnesota)
• Range Truck Group (Washington)
• Mullen Commercial Vehicle Center (California)

Mullen Commercial EVs are available for purchase on Sourcewell under NAFG’s Sourcewell Contract # 091521-NAF which offers Class 1-3 light duty trucks, cars, vans, SUVs, cab chassis, and electric vehicles with related equipment and accessories to U.S. government agencies.

Bollinger Motors

Mullen entered the medium-duty truck classes through its September 2022 acquisition of a controlling interest in EV truck innovator Bollinger Motors. The acquisition gave Mullen access to a significant pipeline of interest from large companies for commercial electric truck classes 3-6 in a wide range of markets, such as last-mile delivery, refrigeration, utilities and upfitters.

The 2025 Bollinger B4 chassis cab is an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input. Bollinger’s unique chassis design protects the 158-kWh battery pack and components to offer unparalleled capability and safety in the commercial market. The vehicle also features a payload in excess of 7,300 pounds with an average driving range of 185 miles. Bollinger Motors began serial production of the B4 on Sept. 16 via its manufacturing partnership with Roush Industries at their facility in Livonia, Michigan.

Bollinger Motors has passed numerous milestones in recent months, including:

• 30 B4s delivered and paid for, worth nearly $4.5 million, since start of production
• Its production launch on Sept. 16 at Roush Industries in Livonia, Michigan
• Achieving FMVSS compliance
• Receiving the Certificate of Conformity from the Environmental Protection Agency, and CARB certification
• The creation of a world-class dealer and service network
• An agreement with Our Next Energy in Novi, Michigan, for battery packs
• Providing a full warranty coverage of the B4 chassis cab
• Announcing Syncron as its warranty administration partner and Amerit Fleet Solutions as its mobile service provider
• A partnership with EO to power EV charging infrastructure, equipment and technology solutions for Bollinger’s dealers and customers

Bollinger Motors has qualified for multiple federal and state incentive programs, including:

• Inflation Reduction Act incentives of up to $40,000 per vehicle
• California: Innovative Small e-Fleet (ISEF) Pilot Program, with incentives up to $120,000 per vehicle
• Massachusetts: voucher of up to $30,000 per vehicle from Massachusetts Offers Rebates for Electric Vehicles (MOR-EV)
• New York: up to $100,000 from NYTVIP through NYSERDA
• Pennsylvania: up to a $20,000 grant from Alternative Fuels Incentive Grant Program (AFIG) of the Pennsylvania Department of Environmental Protection

Mullen FIVE RS

The Mullen FIVE RS is an ultra-high-performance EV Crossover featuring a top speed of over 200 mph and acceleration from 0-60 mph in under 2 seconds. The FIVE RS is equipped with 800-volt architecture, all-wheel drive, two-speed gearbox, and over 1,100 horsepower.

The Mullen FIVE RS is planned for launch in Germany with vehicle sales planned for December 2025. Initial vehicle market territories include the EU in 2025, followed by the UAE and South Africa in early 2026.

Mullen is partnering with Faissner Petermeier Fahrzeugtechnik AG (“FPF”), which has decades of experience in the development and production of serial components and sophisticated vehicles for global brands such as Piech Automotive, Gumpert Automotive and is in partnership with BMW of all the above. FPF is certified according to the IATF standard and fulfills all the special requirements of the Federal Motor Transport Authority in Germany.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

Mullen is led by an executive team with extensive EV, OEM and high-growth startup experience.

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working towards a sustainable future by creating a suite of clean-energy, electric vehicles at varied price points. With entirely US based manufacturing and operations, Mr. Michery is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Bollinger Innovations, Inc. (NASDAQ: BINI), closed Thursday's trading session at $0.14, up 1.3025%, on 479,321 volume. The average volume for the last 3 months is 3,165,520 and the stock's 52-week low/high is $0.01/$138000000000.

Recent News

• Bollinger Innovations, Inc. (NASDAQ: BINI) - France Starts Testing Motorway That Can Charge EVs
• Chinese EVs are Capitalizing on Tech Features to Dominate the Market
• Retired Officers Say Defense Budgets Should Fund Renewable Energy Projects

Strawberry Fields REIT Inc. (NYSE American: STRW)

The QualityStocks Daily Newsletter would like to spotlight Strawberry Fields REIT Inc. (NYSE American: STRW).

Strawberry Fields REIT, Inc., a self-administered real estate investment trust, posted its AFFO for Q2 2025 at $18.4 million, up from $14.3 million during the same period in 2024

From 33 Skilled Nursing Facilities ("SNF") in 2015, the Company has grown its portfolio to 142 healthcare facilities, totaling over 15,500 licensed beds across 10 states in the U.S.

Founder, CEO, and Chairman, Moishe Gubin, built Strawberry Fields with an operator point of view, while focusing on the real estate side of things

By combining a unique knowledge of the healthcare and real estate industries, the Company positioned itself to carve out a growing market share and assert its place as a leader in the industry

The Company is set to announce its Q3 financial results on November 6 after the close of market and hold its quarterly earnings call on November 7

Strawberry Fields REIT (NYSE: AMERICAN: STRW) (the "Company"), a self-administered real estate investment trust engaged in the ownership, acquisition, and leasing of skilled nursing and specific other healthcare-related properties, posted $18.4 million in Adjusted Funds From Operations ("AFFO") for Q2 2025, a significant growth from $14.3 million during the same period in 2024. While announcing the milestone, the Company's Chairman and CEO, Moishe Gubin, lauded the benefits of its master lease structure and acknowledged the Company's strongest quarter since its founding.

Strawberry Fields REIT Inc. (NYSE American: STRW) is a self-administered real estate investment trust engaged in the ownership, acquisition, development, and leasing of skilled nursing and other healthcare-related properties. Initially spun out in 2015 with a 33-property portfolio in Indiana and Illinois, the company has steadily expanded its footprint and now owns and leases across 10 states. Its facilities are leased to experienced third-party operators, primarily under long-term triple-net agreements.

The company’s disciplined strategy emphasizes working with regional operators and experienced consultants, focusing on markets where demographic tailwinds and regulatory barriers support long-term demand. From 2020 through projected 2025, the company achieved compound annual growth rates of 13.6% in Adjusted Funds From Operations (AFFO) and 13.5% in Adjusted EBITDA (AEBITDA).

In August 2025, the board of directors approved a 14.3% increase in the company’s quarterly dividend to $0.16 per share. Chairman and CEO Moishe Gubin stated that the dividend increase reflects the company’s strong performance and sustainable outlook, while still keeping the payout ratio below 50%.

Strawberry Fields REIT is headquartered in South Bend, Indiana.

Portfolio

As of September 2025, Strawberry Fields REIT owns and holds long-term leasehold interests in 142 healthcare facilities totaling more than 15,500 licensed beds. The portfolio includes 130 skilled nursing facilities (SNFs), 10 assisted living facilities (ALFs), and two long-term acute care hospitals (LTACHs), with properties located in Arkansas, Illinois, Indiana, Kansas, Kentucky, Missouri, Ohio, Oklahoma, Tennessee, and Texas.

In recent months, Strawberry Fields REIT has expanded its portfolio through the following acquisitions:

• Nine skilled nursing facilities in Missouri totaling 686 beds for $59 million. Eight of the facilities were added to an existing master lease with the Tide Group, increasing annual base rent by $5.5 million, while the ninth facility was added to Reliant Care Group’s lease, raising rent by an additional $0.6 million.
• An 80-bed skilled nursing facility near Oklahoma City, Oklahoma, for $4.25 million, which was leased to a current operator under a master lease with $425,000 of initial rents and 3% annual escalations.
• A 124-bed facility comprised of 108 skilled nursing beds and 16 assisted living beds near Poplar Bluff, Missouri, for $5.3 million, which was leased to a current operator under a master lease with $530,000of initial rents and 3% annual escalations.

Market Opportunity

Strawberry Fields REIT operates in the skilled nursing and post-acute healthcare real estate sector, which is supported by favorable demographic and regulatory trends. The U.S. population aged 65 and older is expected to exceed 72 million by 2030 and reach 88.5 million by 2050. According to the CDC, 83.5% of skilled nursing facility residents are 65 or older.

The sector benefits from high barriers to entry, including regulatory constraints, capital requirements, and operational complexity. At the same time, government programs such as Medicare and Medicaid provide a stable reimbursement base. The company noted that despite challenges, its operators have demonstrated consistent profitability in states that are traditionally considered difficult for SNF operators.

Spending on SNF care for the aging population is projected to grow from $181.6 billion in 2021 to $273 billion in 2030, reflecting a compound annual growth rate of 4.63%. Strawberry Fields REIT’s geographic clustering strategy and long-term lease structure position it to benefit from this increasing demand and constrained supply.

Leadership Team

Moishe Gubin, Chairman, CEO, and Founder, has served as CEO since the company’s inception and was involved in every acquisition. He previously served as CFO and manager of Infinity Healthcare Management and is a licensed CPA in New York.

Jeffrey Bajtner, Chief Investment Officer and Chief Operating Officer, joined the company in 2021. He oversees acquisitions, dispositions, and investor relations. Previously, he held leadership roles at BlitzLake Partners and NorthStar Realty Finance. He is a licensed CPA in Illinois.

Greg Flamion, Chief Financial Officer, joined in January 2024. He was formerly CFO at Zimmerman Advertising and has held senior finance roles at Diageo and Bristol Myers Squibb. He holds an MBA from the University of Florida and is a CPA licensed in Indiana.

Steven Greenfield, General Counsel, joined in April 2025. He previously served as Managing Attorney at HammondLaw and held executive and legal positions at Weil, Gotshal & Manges LLP and Mayer Brown LLP, focusing on tax and securities law.

Strawberry Fields REIT Inc. (NYSE American: STRW), closed Thursday's trading session at $11.52, off by 1.9574%, on 11,125 volume. The average volume for the last 3 months is 34,501 and the stock's 52-week low/high is $8.7/$12.84.

Recent News

• Strawberry Fields REIT Inc. (NYSE American: STRW) - Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) From Humble Beginnings to $18.4 Million Q2 2025 AFFO; Set to Announce Q3 Financial Results on November 6
• InvestorNewsBreaks - Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) to Report Q3 2025 Results on Nov. 6 and Host Conference Call Nov. 7
• Strawberry Fields REIT Inc. (NYSE AMERICAN: STRW) Eyes $49.29 Billion Elderly Care Market with Ambitious Expansion Plan

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

On October 15, NETEC (National Emerging Special Pathogens Training & Education Center) announced a grant of $37.5 million targeting HCIDs (High-Consequence Infectious Diseases). Laboratories that do work related to high-consequence pathology and pathogens were urged to call upon their employers to apply and be included among the 75 health care facilities that will be selected to receive part of this large grant. The purpose of this award is to upgrade or provide the chosen facilities with what they need to become recognized as Level 2 NSPS centers having special pathogen management systems. The hospitals selected will receive a maximum of half a million dollars to bolster their critical infrastructure, secure specialized equipment that meets the requirements of Level 2 facilities under the NSPS classification, and also undertake the needed training of staff. Shelly Schwedhelm, the NSPS director, revealed that Level 2 facilities are at the core of responding to the threats posed by special pathogens. It should be noted that the notice announcing the grant excludes Level 1 labs and federally-owned facilities. Applications must be submitted by eligible labs on or before December 2 this year. It is commendable that these grants are being made available to boost the fight against special pathogens. The awards come at a time when for-profit entities like Soligenix Inc. (NASDAQ: SNGX) are investing massively in developing novel therapies indicated for biothreats and infectious diseases that are posing a major threat not just within the U.S. but around the world. 

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Thursday's trading session at $1.51, off by 3.8217%, on 247,157 volume. The average volume for the last 3 months is 2,076,086 and the stock's 52-week low/high is $1.09/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - $37.5M Grant Announced to Boost Management of Infectious Diseases in the US
• Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability
• Researchers Develop Nanoparticles That Could Combat Scarring, Inflammation in ARLD

Oncotelic Therapeutics Inc. (OTCQB: OTLC)

The QualityStocks Daily Newsletter would like to spotlight Oncotelic Therapeutics Inc. (OTCQB: OTLC).

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a NetworkNewsWire ("NNW") editorial titled "Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability." The feature highlights how breakthroughs in nanocarrier-based delivery are reshaping cancer therapy by enhancing efficacy and reducing toxicity. Oncotelic's proprietary Deciparticle(TM) platform is spotlighted for its potential to improve the bioavailability and therapeutic index of oncology drugs, advancing the broader shift toward precision nanomedicine.

To view the full press release, visit https://nnw.fm/F5U3f

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy, and targeted therapeutics for cancer and other underserved diseases. The company is focused on transforming outcomes for patients with difficult-to-treat and rare conditions, particularly pediatric cancers and aggressive solid tumors. Its development strategy centers on novel compound design, nanoparticle drug delivery, and the integration of artificial intelligence to accelerate discovery and regulatory workflows.

At the center of this foundation is Chairman and CEO Dr. Vuong Trieu, a prolific industry pioneer who has filed more than 500 patents with 75 issued patents across biologics, small molecules, nanoparticles, and diagnostics. Dr. Trieu co-invented Abraxane® (sold to Celgene for $2.9 billion), underscoring his track record of creating high-value therapies. Through collaborations with industry leaders and its stake in specialized joint ventures, Oncotelic is positioned to advance a diverse portfolio of oncology assets with greater speed and cost efficiency. The company also operates a proprietary AI platform, PDAOAI, which streamlines scientific writing, regulatory documentation, and data interpretation. This system is accessible to the public through a dedicated Discord server, offering real-time engagement with Oncotelic’s research ecosystem.

With expanded clinical activity and a next-generation development model, Oncotelic continues to evolve as a multi-asset innovator in precision oncology.

The company is headquartered in Agoura Hills, California.

Pipeline and Partnerships

Oncotelic’s lead candidate is OT-101, currently in a Phase 3 trial for pancreatic ductal adenocarcinoma (STOP-PC study) and evaluated in gliomas and metastatic solid tumors in combination with IL-2 and checkpoint inhibitors. The antisense molecule targets TGF-β2, a cytokine known to suppress immune responses and promote tumor growth. A Phase 1 trial combining OT-101 with IL-2 was recently completed, demonstrating safety and paving the way for combination therapies with PD-1 blockers and other immunotherapies.

Recent data have further strengthened the rationale for OT-101 in pancreatic ductal adenocarcinoma (PDAC). In June and July 2025, two peer-reviewed studies published in the International Journal of Molecular Sciences identified TGF-β2 gene expression and methylation status as significant prognostic markers in PDAC, particularly among younger patients and those with low CD8+ T-cell infiltration. High TGF-β2 expression correlated with reduced overall survival, while elevated TGF-β2 methylation was associated with improved outcomes. These findings validate TGF-β2 as a high-priority target and support the continued development of OT-101 as a precision therapy. Both studies leveraged Oncotelic’s proprietary AI-driven platform, PDAOAI, to mine and assemble multi-omic datasets, showcasing the system’s role in accelerating insight generation.

The company holds a 45% ownership stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited. GMP Bio owns SAPU Bioscience, which is executing several pipeline programs. SAPU and Oncotelic are jointly utilizing a rapid IND platform through their partnership with Shanghai Medicilon to support regulatory filings for up to 20 drug candidates, with five INDs already underway. This collaboration is central to accelerating development of next-generation anticancer agents.

After the joint venture, Dr. Trieu, with his team, built out a state of the art and GMP-certified R&D facility in San Diego, which operates under SAPU, that manufactures clinical trial materials and supports a proprietary nanoparticle platform trademarked Deciparticle ™. This platform includes four therapeutic candidates—two of which are in late-stage manufacturing and expected to enter IND filing before the end of 2025.

Additionally, Oncotelic owns AL-101, an intranasal administered apomorphine product intended for the treatment of Parkinson’s disease, Erectile Dysfunction, and Female Sexual Disorders.

Market Opportunity

Oncotelic is targeting large and underserved therapeutic markets with significant commercial potentials. The global pancreatic cancer treatment market alone is projected to grow at a 12.3% CAGR, reaching $5.84 billion by 2030, up from $2.92 billion in 2024, according to Research and Markets. This growth is driven by increased disease prevalence, aging populations, and demand for more effective treatment options. Notably, the incidence of early-onset PDAC is rising at an estimated rate of 4% per year in the 15–34 age group, highlighting an emerging unmet need for targeted therapies among younger patients.

Beyond oncology, Oncotelic intends to develop AL-101 for Parkinson’s disease, which affects over 1 million patients in the U.S. alone and is expected to impact 1.2 million by 2030. Erectile Dysfunction and Female Sexual Dysfunction are also major global health issues, with Erectile Dysfunction affecting up to 70% of men over 60 and Female Sexual Dysfunction impacting approximately 40% of women—both with limited treatment options, particularly for patients who fail to respond to existing medications. These underserved populations offer fertile ground for innovative new therapies.

Leadership Team

Dr. Vuong Trieu is the Chairman and CEO of Oncotelic Inc. An accomplished innovator in pharmaceutical development, Dr. Trieu previously served as President and CEO of Igdrasol, where he pioneered the approval path for paclitaxel nanomedicine via a single bioequivalence trial. After Igdrasol merged with Sorrento Therapeutics, he became Chief Scientific Officer and a Board Director. He also held leadership roles at Cenomed, Abraxis, Applied Molecular Evolution, and Parker Hughes Institute. Dr. Trieu holds a Ph.D. in Molecular Microbiology, a B.S. in Botany, has published widely, and filed over 500 patent applications with 75 issued U.S. patents.

Amit Shah is the Chief Financial Officer of Oncotelic Inc. He has over 20 years of financial leadership in life sciences, including CFO roles at Marina Biotech and Igdrasol, and senior positions at ISTA Pharmaceuticals, Spectrum Pharmaceuticals, and Caraco. He also worked in consulting and ERP implementation. Mr. Shah holds a Bachelor of Commerce from the University of Mumbai, is an Associate Chartered Accountant in India, and is an inactive CPA in Colorado.

Dr. Anthony E. Maida III is the Chief Clinical Officer – Translational Medicine at Oncotelic Inc. He has over 25 years of experience advancing cancer immunotherapies and held senior roles at Northwest Biotherapeutics, PharmaNet, and Jenner Biotherapies. He has raised over $200 million for biotech firms and negotiated licensing deals with institutions such as Pfizer, Eli Lilly, and Yale. Dr. Maida holds dual B.A. degrees in Biology and History, an MBA, an M.A. in Toxicology, and a Ph.D. in Immunology, and is active in ASCO, AACR, and other scientific societies.

Oncotelic Therapeutics Inc. (OTCQB: OTLC), closed Thursday's trading session at $0.0997, off by 0.1002004%, on 149,306 volume. The average volume for the last 3 months is 262,350 and the stock's 52-week low/high is $0.02/$0.11.

Recent News

• Oncotelic Therapeutics Inc. (OTCQB: OTLC) - NetworkNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Advances
• NetworkNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Innovations in Oncology
• InvestorNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium

Safe and Green Holdings Corp. (NASDAQ: SGBX)

The QualityStocks Daily Newsletter would like to spotlight Safe and Green Holdings Corp. (NASDAQ: SGBX).

Safe and Green Holdings Corp. (NASDAQ: SGBX) is a diversified holding company focused on delivering innovative solutions across infrastructure, construction, energy, healthcare, and environmental sectors. Originally established in 2007 as SG Blocks, the company has evolved into a vertically integrated platform serving both public and private sector clients with modular, sustainable systems. Its operations span a range of industries unified by a commitment to efficient, scalable design and sustainability-driven development.

The company’s model centers on the production and deployment of prefabricated modular structures, energy systems, and infrastructure technologies, leveraging vertical integration and cross-sector synergies to support government agencies, medical networks, developers, and commercial enterprises. Safe and Green’s subsidiaries operate collaboratively to generate multiple revenue streams while pursuing opportunities in both traditional and next-generation infrastructure.

Safe and Green Holdings Corp. is headquartered in Miami, Florida.

Portfolio

SG Echo Manufacturing

SG Echo is the modular manufacturing arm of Safe and Green Holdings Corp., delivering prefabricated structures built from steel, wood, and repurposed shipping containers. As a Made-in-America manufacturer, SG Echo combines industry-leading machinery and skilled labor to execute modular projects for clients across the U.S. and globally. The company holds an ESR certification from the International Code Council for repurposed containers, enabling faster approvals and widespread applicability in commercial and industrial construction.

With the ability to reduce construction time by up to 50% and cut costs by 10–20%, SG Echo’s manufacturing process emphasizes speed, sustainability, and resilience. In October 2025, SG Echo’s operations were consolidated into a new facility in Conroe, Texas, where they now operate alongside Olenox Corp., a Safe and Green subsidiary focused on oil and gas operations, to streamline logistics and integrate manufacturing with field operations. Revenue is also generated through third-party property leasing at the Conroe site.

SG Modular Medical

SG Modular Medical designs and deploys modular point-of-care solutions tailored for the evolving demands of healthcare infrastructure. The system enables clinics and labs to be rapidly assembled from clinical, administrative, and diagnostic modules, offering adaptability based on local needs and population shifts. This modular approach is positioned as a lower-emission alternative to traditional medical construction, helping reduce the substantial carbon footprint associated with healthcare infrastructure.

Notable deployments include COVID-19 testing pods at Los Angeles International Airport (LAX), designed and delivered in partnership with airport authorities. Another initiative, launched with The Peoples Healthcare and Teamsters Local 848, involves delivering modular clinics to serve union members with onsite, high-quality care staffed by a top-tier clinical operator.

SG Development Corp.

SG DevCorp is the real estate development division of Safe and Green Holdings Corp., focused on building modular single- and multifamily projects across various income levels. The company pursues strong, green developments supported by vertically integrated manufacturing from SG Echo. SG DevCorp has stated development targets of more than 4,000 modular units totaling over 3.2 million square feet across 1,000+ acres of acquired land—a construction pipeline valued at approximately $765 million.

The division prioritizes sustainability throughout the lifecycle of its developments, reducing construction waste, energy usage, emissions, and noise pollution. Its projects aim to minimize the environmental impact while enhancing speed-to-market and structural resilience.

SG Environmental Solutions

SG Environmental Solutions provides modular environmental infrastructure and sustainable waste management technologies. At the core of this division is Sanitec, a patented system designed for medical waste sterilization and volume reduction. The technology helps organizations reduce their environmental impact while significantly lowering operational costs.

The company emphasizes responsible construction and stewardship through upcycling, waste reduction, and adaptable modular deployments. Its container-based platforms are built for diverse use cases across commercial, residential, industrial, and environmental applications, with a focus on high-efficiency, reduced-emission outcomes.

Olenox Energy

Olenox Energy is the energy development arm of Safe and Green Holdings, focused on acquiring and revitalizing distressed oil and gas assets. In May 2025, the company acquired 1,600 acres of wells and leases from Sherman Oil & Gas and its affiliates, adding 111 wells to the Olenox portfolio. Since the acquisition, Olenox has produced over 3,000 barrels of oil and is currently achieving peak production rates of 55 barrels per day. The company is preparing additional workovers to add 25–30 bpd and has completed full asset mobilization into Texas. Olenox also holds a 51% stake in Winchester Oil & Gas, representing more than 500 wells across the state.

The company is executing its strategy to build a fully integrated oil and gas platform. Olenox operations remain in full compliance with the Texas Railroad Commission, with a stated emphasis on environmental stewardship and reduced lease operating expenses.

In September 2025, Safe and Green entered into an Open Collaborative Framework with OneQode, a global digital infrastructure company. The agreement supports joint development of spill detection, real-time telemetry, and command systems for remote energy assets, enhancing Olenox’s operational capabilities through automation and data infrastructure.

Market Opportunity

Safe and Green Holdings is positioned to capitalize on macro trends across multiple sectors. The construction and real estate industries continue to seek faster, greener alternatives to traditional building methods—needs that SG Echo and SG DevCorp address through prefabricated, modular designs. In healthcare, rising demand for scalable care infrastructure underscores the relevance of SG Modular Medical’s point-of-care solutions.

Within energy, Olenox targets long-term value in revitalizing overlooked oil and gas assets. Its operational model, combined with emerging infrastructure technology partnerships, aims to improve field performance while maintaining environmental compliance. Through this diversification, Safe and Green aligns its platform with infrastructure modernization, energy resilience, and sustainability imperatives.

Leadership Team

Michael McLaren, Chairman and Chief Executive Officer, brings over 30 years of leadership in the energy industry, including military and field service projects, mergers and acquisitions, and technology development. He is the founder of Olenox Ltd., a developer of proprietary energy systems, and holds advanced degrees in Science and Business from the University of British Columbia. McLaren has authored multiple papers on alternative fuels and energy systems and serves as a lead strategist for Safe and Green’s cross-sector growth.

Patricia Kaelin, CPA, Chief Financial Officer, has more than 30 years of experience in public company financial management, mergers and acquisitions, and strategic capital deployment. She previously served as CFO and CIO of a billion-dollar construction company overseeing operations across 14 states. Her background spans construction, healthcare, manufacturing, and real estate. Kaelin holds a bachelor’s degree in business administration with a concentration in accounting from California State University, Fullerton.

Jim Pendergast, Chief Operating Officer, has held executive leadership roles across multiple sectors, including energy, construction, and agriculture. He has served as COO, CFO, and CEO at public and private firms, overseeing operations, acquisitions, and project execution. He holds an MBA in international business and finance from McMaster University and a BA in political studies and economics from Queen’s University.

Safe and Green Holdings Corp. (NASDAQ: SGBX), closed Thursday's trading session at $2.29, off by 7.2874%, on 597,498 volume. The average volume for the last 3 months is 6,855,317 and the stock's 52-week low/high is $2.03/$122.88.

Recent News

• Safe and Green Holdings Corp. (NASDAQ: SGBX) - Safe & Green Holdings Corp. (NASDAQ: SGBX) Subsidiary Olenox Energy Sets Aggressive Drilling Agenda for Q4 2025 and Beyond
• InvestorNewsBreaks - Safe & Green Holdings Corp. (NASDAQ: SGBX) and Olenox Reaffirm OneQode Partnership to Advance Digital Infrastructure Resilience
• Safe & Green Holdings Corp. (NASDAQ: SGBX) Consolidates Operations, Expands Olenox AI Capabilities

FAVO Capital Inc. (OTC: FAVO)

The QualityStocks Daily Newsletter would like to spotlight FAVO Capital Inc. (NASDAQ: FAVO).

FAVO Capital Inc. (OTC: FAVO) is redefining the private credit and alternative lending industry through a strategic redevelopment of its operations and offerings. With a focus on leveraging financial technology and a client-centric approach, FAVO Capital empowers small to medium-sized businesses with fast, flexible, and reliable access to capital, bridging the gap left by traditional financial institutions.

Empowering Businesses, Redefining Private Credit

As part of its strategy to uplist to Nasdaq, FAVO Capital is enhancing its technology platform, operational scalability, and market positioning to meet higher regulatory standards and attract institutional investors. Headquartered in Fort Lauderdale, Florida, FAVO employs over 120 professionals across five global offices, delivering sustainable growth and value for clients and shareholders alike.

Products and Services

• Proprietary Lending Platform and Mobile App (In Development): FAVO Capital is in the early stages of developing an advanced digital platform designed to enhance client engagement and streamline funding processes. This platform will eventually allow businesses to apply for funding products, track progress, and manage repayment efficiencies. A complementary mobile app is also being planned to provide real-time insights and tailored recommendations, laying the groundwork for an improved borrower experience.
• Fintech-Driven Lending Solutions: FAVO Capital is exploring proprietary and third-party technology tools, including advanced analytics and algorithms, to enhance decision-making speed and reliability in the lending process.
• Flexible Financing Options: FAVO specializes in structuring customized capital solutions tailored to the diverse needs of small business owners, offering scalable and adaptable products that evolve with changing market conditions.

Market Opportunity

The private credit market is experiencing exponential growth as traditional banks reduce their focus on small business lending. According to industry reports, the global private credit market is projected to surpass $1.5 trillion by 2025, driven by increasing demand for alternative financing options.

FAVO Capital is uniquely positioned to capture market share within this booming sector by leveraging fintech innovation to meet the needs of underserved small businesses. With a focus on efficiency, speed, and client satisfaction, FAVO addresses critical gaps in the financial ecosystem while building a platform for long-term growth.

Recent Highlights

• Fintech Innovation: Initial investments in app development and analytics lay the groundwork for future operational efficiency and improved borrower experience.
• Operational Scale: A global footprint with over 120 employees combines the agility of a local lender with the reach of an international financial institution.
• Proven Growth: FAVO’s technology-driven approach has enabled consistent expansion, solidifying its reputation as a trusted partner for small businesses.

Leadership Team

Vincent Napolitano is a Founder and CEO of FAVO Capital Inc. With over two decades of experience in finance and business development, Vincent has been instrumental in building FAVO Capital into a trusted partner for businesses seeking innovative financial strategies. Prior to founding FAVO Capital, Vincent spent 25 years on Wall Street, holding key positions at prominent firms and developing expertise in structuring complex financial deals. He also served as Chief Investment Officer for multiple special purpose vehicles (SPVs), acquiring private stock in pre-IPO unicorn companies such as Facebook and Twitter.

Shaun Quin is a Founding Member and President of FAVO Capital Inc., overseeing the company’s mission to deliver innovative and efficient private credit solutions to small and medium-sized businesses. With over 20 years of global experience as a partner, investor, and director, Shaun brings a strategic and customer-focused approach to his leadership. His expertise in fostering collaboration, building high-performance cultures, and empowering businesses has positioned FAVO Capital as a trusted leader in private lending.

Vaughan Korte, CFO, brings over 15 years of global financial expertise to his role with FAVO Capital Inc. His track record includes managing financial operations for Adidas across 60 countries with budgets exceeding $500 million. Vaughan’s leadership ensures FAVO Capital remains financially resilient, aligning financial strategy with organizational goals and fostering shareholder value.

Glen Steward, Chief Strategy Officer, is a seasoned entrepreneur with over 28 years of experience in the investment and trading industries. He drives FAVO Capital’s strategic initiatives, ensuring the company remains competitive and agile in a rapidly evolving market. Glen has held directorships and board memberships across Mauritius, South Africa, and the United States. His strategic acumen has been pivotal in integrating the FAVO Group of Companies into FAVO Capital Inc., fueling growth and market leadership.

Advisory Board

Bilal Adam, Accounting & Financial Counsel, is a financial expert with over 20 years of experience, including roles as CEO of Stewards Investment Capital. His insights into bespoke investment solutions, including fixed income, equity, and digital assets, support FAVO Capital’s innovative approach to private credit.

Honorable Earnest Hart, Corporate Governance Counsel, brings decades of legal and governance experience, having served as a New York Supreme Court Judge and COO at Columbia University Medical Center. His guidance ensures FAVO Capital maintains robust corporate governance standards.

Rocco Trotta, Business Leadership and Scalability Counsel, is the co-founder of LiRo-Hill and has decades of experience scaling businesses. His expertise in organizational efficiency and talent development strengthens FAVO Capital’s ability to attract excellence across all aspects of the business.

As FAVO Capital redevelops its operations and prepares for an uplisting to Nasdaq, the company is laying the foundation to redefine private credit with emerging fintech solutions and exceptional leadership. Learn more by visiting investors.favocap.com.

FAVO Capital Inc. (OTC: FAVO), closed Thursday's trading session at $4.35, off by 0.8547009%, on 1,252 volume. The average volume for the last 3 months is 5,560 and the stock's 52-week low/high is $0.162/$5.3.

Recent News

• FAVO Capital Inc. (OTC: FAVO) - InvestorNewsBreaks - FAVO Capital (OTC: FAVO) Appoints Gary F. Baumann as Independent Director
• NetworkNewsBreaks - FAVO Capital (OTC: FAVO) Appoints Dr. Wael Barsoum as Independent Director 
• InvestorNewsBreaks - FAVO Capital (OTC: FAVO) Appoints Zachary Graeve as Independent Director and Governance Chair 

Astiva Health

The QualityStocks Daily Newsletter would like to spotlight Astiva Health

Astiva Health is a dynamic and innovative Medicare Advantage Prescription Drug (MAPD) health plan committed to reshaping the landscape of personalized and comprehensive healthcare. The company offers full medical, drugs, and supplemental benefits for Medicare enrollees, currently serving counties in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino. This broad coverage reflects Astiva Health’s dedication to reaching a diverse demographic and addressing the healthcare needs of individuals across Southern California.

Astiva Health primarily serves a heretofore underserved Asian American and Pacific Islander population, which positions it in a critical and expanding market segment and offers substantial growth potential. The company recognizes the diverse needs within its served communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions.

Astiva Health cares about its members and works to establish lifelong relationships with them by providing a tailored approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Health is an essential key to living a good life, and Astiva Health makes it a priority to help members love the life they live.

The company’s mission is to deliver an unparalleled level of quality care to its members. Astiva Health’s Medicare Advantage plans provide lower costs and additional benefits beyond original Medicare coverage.

Founded in southern California, Astiva Health has strategically positioned itself in a region with a dynamic and diverse population. The organization’s extensive network and culturally responsive approach to healthcare make it well-suited to cater to the needs of the local community, creating a competitive advantage in the market.

The company is based in Orange, California.

Healthcare Model

Astiva Health is not just another health plan. The company considers the uniqueness of its members and, therefore, the means for delivering quality care to each one. To best serve its members, Astiva Health has developed one of the most diverse networks in southern California, offering a selection of medical, drugs, and supplemental benefits including dental, acupuncture, vision and hearing plans tailored to the specialized needs of individual members.

The company’s health plans provide increasing levels of benefits to members in the counties it serves. Astiva Health’s Customer Care Support and representatives are available to assist members with any issues.

The organization’s proactive approach to overcoming language barriers for the Vietnamese communities demonstrates a commitment to inclusivity and enhances accessibility – a key factor for future growth. The successful implementation of strategies for the Vietnamese community sets a precedent for Astiva Health’s ability to adapt and apply similar approaches to serve other ethnic groups in future expansions, broadening the potential impact of its services.

The company provides members access to experienced and dedicated providers and local pharmacies that work together with each member to pave a pathway toward better health. The company’s online directory provides members with a comprehensive list of providers to fit their specialized needs.

Astiva Health collaborates with a variety of partners who offer supplemental benefits to members beyond Medicare. Those benefits include transportation, vision, dental, hearing, fitness, tele-health, acupuncture and chiropractic. Astiva’s forward-thinking strategy not only fulfills a critical societal need but also ensures sustainable growth and transformative impact across diverse communities.

Market Opportunity

Medicare Advantage plans, since their establishment in 2008 as a lower-cost alternative for Medicare enrollees looking to save on monthly premiums, have been one of the fastest growing segments of the health insurance market.

According to a report by healthcare consultant Charts, nearly 31 million beneficiaries are enrolled in a Medicare Advantage plan in 2023, accounting for more than 48% of the total Medicare market. That represents 9.6% enrollment growth over 2022 totals, and the pace of growth is likely to continue, according to the Charts report.
Startup Medicare Advantage plans, a sector that includes Astiva Health, grew even faster for 2023, at a rate of 22% over 2022 totals.

Management Team

Dr. Tri T. Nguyen is co-founder and CEO of Astiva Health. He is a graduate of Stanford Medical School and is a board-certified expert in internal medicine, cardiovascular disease and interventional cardiology. As founder, CEO and owner/operator of Avanta IPA, he is a committed leader in healthcare. His visionary leadership, hands-on experience and deep industry knowledge uniquely position him to guide Astiva to success.

Chi Luong is CFO at Astiva Health. She founded and operates HADD Group LLC, a company managing medical clinic services, including business contracting, finance, staffing and ancillary support for several medical clinics in San Diego. She is responsible for the expansion and daily operation of the business functions of the medical clinics managed by HADD Group, and she has extensive knowledge and experience in healthcare business development.

Viet Tran has over 30 years of experience in engineering research, development and management. He has made numerous contributions to national network security and technology. He led the initial Naval Interoperability Profiles that set a solid foundation for future naval airborne network development. He also led a team of 50 engineers, doctorates and scientists delivering an airborne network system for the Navy’s first carrier-based unmanned aircraft. As Astiva Health’s Chief Operating and Technology Officer, member satisfaction has been his top priority. He is committed to protecting valuable data for Astiva members and providers. He constantly strives for leaner and more effective operations.

Tyler Diep is Vice President, Sales, Marketing and Provider Relations at Astiva Health. His responsibilities include handling special projects for the board of directors, as well as overseeing the sales, marketing and provider relations department. During his tenure, he tripled the membership of Astiva Health. He previously served as councilman and vice mayor of the City of Westminster, California. He immigrated to the U.S. with his parents and graduated from San Diego State with a bachelor’s degree in public administration.

Recent News

• Astiva Health - New Report Highlights Concerning Trends in the US Health Care System
• Why Health Insurance Credits Led to the Federal Government Shutdown
• Health Care Titans are Filing for Bankruptcy in America